Correction to Lancet Haematol 2016; 3: e323

Corrections

Correction to Lancet Haematol 2016; 3: e323 Greil R, Obrtlíková P, Smolej L, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol 2016; 3: e317–29—The Results section of this Article stated that “MRD progression more frequently occurred within the observation group (94 patients in the rituximab group vs 62 in the observation group; p<0·0001)”. This should have read “MRD progression more frequently occurred within the observation group (62 patients in the rituximab group vs 94 in the observation group; p<0·0001)”. This correction has been made to the online version as of July 1, 2016.

www.thelancet.com/haematology Published online July 1, 2016 http://dx.doi.org/10.1016/S2352-3026(16)30076-X

Lancet Haematol 2016 Published Online July 1, 2016 http://dx.doi.org/10.1016/ S2352-3026(16)30076-X

1